The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The prognostic value of MRD in CLL
Joanna Rhodes, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, discusses the value of measurable residual disease (MRD) in prognosticating outcomes for patients with chronic lymphocytic leukemia (CLL). She mentions several trials (CLL13; NCT02950051, UK FLAIR; ISRCTN01844152, CLARITY; ISRCTN13751862, CAPTIVATE; NCT02910583) which provide evidence for the prognostic value of MRD negativity, including in patients treated with chemoimmunotherapy, and venetoclax-based fixed-duration regimens. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
